V. Valero
68 works · 1,063 citations · h-index 12
Top works
- Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy
- Clinical outcome of patients with lymph node‐negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry
- Circulating tumor cells and bone metastases as detected by FDG–PET/CT in patients with metastatic breast cancer
- Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response.
- A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefinitib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
- A new measurement of residual cancer burden to predict survival after neoadjuvant chemotherapy
- Clinical course of breast cancer patients with metastases confined to the lungs treated with chemotherapy
- Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
- Mesenteric laceration complicating a heimlich maneuver
- Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors.
- Abstract S6-02: Long-term prognostic value of residual cancer burden (RCB) classification following neoadjuvant chemotherapy
- Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin.
- Ecological momentary assessment of sleep, symptoms, and mood during chemotherapy for breast cancer
- Prognostic value of circulating tumor cells (CTC) in metastatic breast cancer (MBC): Correlation with immunohistochemically defined molecular subtypes and metastatic disease sites.
- Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors
- Exploratory subset analysis according to prior endocrine treatment of two randomized phase II trials comparing gefitinib (G) with placebo (P) in combination with tamoxifen (T) or anastrozole (A) in hormone receptor-positive (HR+) metastatic breast cancer (MBC)
- Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression
- Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel
- Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line therapy.
- Abstract P2-13-02: Chemotherapy-related amenorrhea (CRA) after adjuvant trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT trial)